A structural comparative approach to identifying novel antimalarial inhibitors

Area of Science:

• Parasitology
• Drug Discovery
• Structural Biology

Background:

• Malaria remains a significant global health burden, affecting millions annually.
• Emerging drug-resistant malaria strains necessitate the development of novel therapeutic strategies.
• PfUCHL3, an essential deubiquitinating enzyme in Plasmodium falciparum, presents a promising drug target.

Purpose of the Study:

• To identify novel small molecule inhibitors that specifically target the malaria parasite enzyme PfUCHL3.
• To leverage a structural comparative approach for drug discovery against essential parasitic targets.
• To find inhibitors with preferential binding to PfUCHL3 over its human ortholog, UCHL3.

Main Methods:

• Virtual screening of the National Cancer Institute (NCI) library (~320,000 compounds) against the PfUCHL3 crystal structure using AutoDock Vina.
• Secondary screening of top-ranking compounds against the human ortholog UCHL3 to assess selectivity.
• In vitro activity assays to determine the efficacy of selected inhibitors.

Main Results:

• Several compounds exhibited significant binding affinity preference for PfUCHL3 compared to human UCHL3.
• Two identified compounds demonstrated potent inhibitory activity with activity in the nanogram per milliliter (ng/mL) range.
• The virtual screening approach successfully identified selective inhibitors for the parasitic target.

Conclusions:

• The study successfully identified selective small molecule inhibitors of PfUCHL3 using a structure-based virtual screening approach.
• These compounds represent potential leads for the development of new antimalarial drugs, particularly against resistant strains.
• The findings highlight the utility of comparative structural analysis in discovering targeted antiparasitic agents.